Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

• Other: Placebo
  
  0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
• Drug: 25 mg PF-05231023
  
  25 mg IV once a week for 4 weeks
• Drug: 50 mg PF-05231023
  
  50 mg IV once a week for 4 weeks
• Drug: 100 mg PF-05231023
  
  100 mg IV once a week for 4 weeks
• Drug: 150 mg PF-05231023
  
  150 mg IV once a week for 4 weeks

• Placebo Comparator: Placebo Arm
  
  Intervention: Other: Placebo
• Experimental: 25 mg
  
  Intervention: Drug: 25 mg PF-05231023
• Experimental: 50 mg
  
  Intervention: Drug: 50 mg PF-05231023
• Experimental: 100 mg
  
  Intervention: Drug: 100 mg PF-05231023
• Experimental: 150 mg
  
  Intervention: Drug: 150 mg PF-05231023

Inclusion Criteria:

• Male and female subjects of non-childbearing potential between the ages of 30 and 70 years with and without a diagnosis of Type 2 diabetes mellitus (according to the American Diabetes Association guidelines).
• Subjects with poor lipid control as confirmed by laboratory tests.
• BMI of 30 to 40 Kg/m2 and a total body weight of >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding asymptomatic, seasonal allergies at time of dosing).
• Levels of blood enzymes indicating pancreatitis or elevated liver function enzymes outside of the laboratory's reference range as confirmed by laboratory tests.
• Subjects with Type 1 Diabetes Mellitus.